“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Having held strategy and business development positions within various healthcare world leaders in Asia and Europe, I am today Chief Executive Officer at ImCheck Therapeutics, a biotechnology company that designs and develops a new generation of immunotherapy antibodies discovered by Professor Daniel Olive at the Paoli-Calmettes Institute. These new antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T killer lymphocytes, and a novel superfamily of immunomodulators, butyrophilins. Due to their novel mechanism of action, in particular their ability to simultaneously modulate innate and adaptive immunity, our activating antibodies may be superior to existing immune checkpoint inhibitors and, when used in combination, they may overcome resistance to these agents. Finally, beyond cancer, we have demonstrated in preclinical studies that, in their inhibitory version, our antibodies could also improve the treatment of several autoimmune diseases.
To date, ImCheck has raised nearly €80 million from top tier European and American investors and the first clinical trial of our drug candidate ICT01 will be launched in 2020. Thus, barely 5 years after its creation, ImCheck has already gone through all the steps that lead from discovery to the clinic.
As a co-founder of Marseille Immunopole, ImCheck is a perfect symbol of our cluster’s mission: strengthen Marseille’s leadership in immunotherapy by combining the best of immunology research with sound expertise in research and development of both therapeutic antibodies and diagnostics assays in immuno-oncology, and an utterly international ambition.#industrie
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
The Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma
Bernard A. FOX
Providence Cancer Institute, Portland, Oregon | UbiVac
Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.
AMU, IPC, CRCM
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.